Table 6. Grading of recommendations, assessment, development and evaluation (GRADE) evidence quality ratings for local and distant brain control outcomes.
Six-month Local control | 12-month Local control | 6-mo DBC | 12-month DBC | |
Studies demonstrating significant improvement | 0/1 | 0/2 | 0/1 | 0/2 |
SRS and Ipilimumab patients | 25 | 45 | 25 | 45 |
SRS alone patients | 33 | 67 | 33 | 67 |
Initial quality of evidence | Low (two plus) | Low (two plus) | Low (two plus) | Low (two plus) |
Risk of bias | Serious (-1) | Serious (-1) | Serious (-1) | Serious (-1) |
Inconsistency | Serious (-1) | Serious (-1) | Serious (-1) | Serious (-1) |
Indirectness | Not serious | Not serious | Not serious | Not serious |
Imprecision | Serious (-1) | Serious (-1) | Serious (-1) | Serious (-1) |
Publication bias | Not likely | Not likely | Not likely | Not likely |
Large effect | Not likely | Not likely | Not likely | Not likely |
Dose response | No gradient | No gradient | No gradient | No gradient |
All plausible residual confounding | N/A | N/A | N/A | N/A |
GRADE overall quality of evidence | Very Low | Very Low | Very Low | Very Low |